Skip to main content
OpenTrials
Completed

NCT Number: NCT04787523

Rectrospect - a Retrospective Study of Treatment Response

Biopisies from patients diagnosed with rectal cancer between 2007-2019 will be cut into 4-6 micrometer thin sections for morphology and immunostaining. Every section will be numbered with a code that is connected to the patients personal identification number and the code list will be kept separately from the biopsies in a password protected file on the Sahlgrenska University Hospital server.

Patient data and outcome regarding response to treatment will be collected from patient charts and the Swedish ColoRectal Cancer Registry, but all data will be numbered with the same code number and all results will be kept away from the code list. In order to achieve the stated aims, that is, to study how the molecular and cellular characteristics of the tumour and its surrounding microenvironment as well as the interaction of tumour cells and immune cells affect treatment response, several molecular and cellular techniques and assays may be applied.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rectal Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Dept. of Surgery, Sahlgrenska University Hospital/Ostra

Gothenburg, SE 416 85, Sweden

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Rectal cancer and treatment between 2007 and 2019

Exclusion criteria

  • No rectal cancer or no neoadjuvant treatment

Treatment and study plan

Radiotherapy

Radiation

Patients have received neoadjuvant radiotherapy

Primary outcomes

  1. Immun cell infiltrate in pathology sections from the tumour

    Time frame: Biopsies taken preoperatively

    Number of of CD3+ and CD8+ cells in the tumour in relation to response to treatment

Sponsors and collaborators

Lead sponsor

Sahlgrenska University Hospital

Other

Registry information

Official study title

Rectrospect - a Study on the Immun Cell Infiltrate in a Retrospective Rectal Cancer Cohort.

Acronym: Rectrospect

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Mar 8, 2021
Registry last updated
Nov 7, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.